基底鳞状细胞癌1例

基底鳞状细胞癌是指基底细胞癌中有鳞状细胞癌（简称鳞癌）的成分，占基底细胞癌的10%-20%，生长较快，临床表现同基底细胞癌，但转移同鳞癌，本病临床较为少见，1996年世界卫生组织将其列为独立病种。现将我们诊治的1例报告如下。     

皮肤基底细胞癌和鳞状细胞癌的研究现状

基底细胞癌和鳞状细胞癌是最常见的非黑素瘤皮肤癌。近年来 ,其发病率持续上升 ,引起临床较多的关注。研究发现紫外线照射、人类乳头瘤病毒感染、癌基因突变等因素与它们的发病密切相关。诱发该类疾病的机制也是多种多样的。除了传统治疗方法 ,Mohs外科切除术、光动力学疗法、新药的应用等也为该病的治疗提供了新方法。另外 ,采取积极的预防措施可有效地防止基底细胞癌和鳞状细胞癌的发生     

鳞状细胞分化基底细胞癌

报告1例鳞状细胞分化的基底细胞癌。患者男,85岁。因“发现上唇肿块2年”入院。皮肤科检查：上唇中部可见一约2 cm×4 cm淡红色肿块,境界清楚,上连鼻基底及鼻小柱,下连唇红,中心凹陷,周边隆起,基底破溃,伴有渗血、渗液和结痂。右侧唇红可见一直径约0.5 cm皮肤缺损,境界清楚,可见渗液及痂皮覆盖。皮损组织病理检查示肿瘤细胞似基底细胞栅栏状排列,细胞核质比增大,核异形明显,同时夹杂着含有大量嗜酸性细胞质的鳞状细胞聚集,异形性明显。免疫组化：细胞角蛋白（CK）5/6、肿瘤蛋白P63、角蛋白-903(34βe12)、表皮生长因子受体（EGFR）、细胞增殖标记Ki-67、肿瘤蛋白P40、肿瘤抑制蛋白P53和上皮细胞黏附分子Ber-EP4均为阳性,神经特异性烯醇化酶（NSE）、糖基化跨膜蛋白CD34、上皮膜抗原（EMA）均为阴性。诊断：鳞状细胞分化基底细胞癌。治疗方案：肿物切除+皮瓣转移修复,随访1年未见复发。     

皮肤基底细胞癌和皮肤鳞状细胞癌270例回顾性分析

 目的:总结我院皮肤基底细胞癌(BCC)和皮肤鳞状细胞癌(SCC)临床与组织病理资料,以期提高BCC与SCC的诊断率。方法：回顾性分析2014年1月1日-2018年12月31日间我院皮肤科门诊经组织病理切片确诊的170例BCC与100例SCC患者的临床与病理资料。结果：BCC与SCC年度发病整体均呈逐渐上升趋势。BCC、SCC男女患病比例分别为0.8∶1、1∶1，好发部位均为曝光部位(头面颈部和四肢)，临床诊断与组织病理诊断符合率分别为62.4%与30.0%。临床诊断上，BCC易与脂溢性角化病(SK)、色素痣混淆；SCC易与BCC、鲍温病、光线性角化病(AK)混淆。结论：BCC和SCC为临床常见的非黑素性皮肤肿瘤，但易误诊和漏诊。临床医生对于可疑病灶应尽早行皮损组织病理检查。     

热休克蛋白27在皮肤基底细胞癌和鳞状细胞癌中的表达

热休克蛋白(heat shock proteins,HSP)是细胞在应激状态下产生的一组高度保守的蛋白质家族中的成员,主要在蛋白质合成、折叠、装配、退化、信号转导等方面发挥调节作用.HSP27在调节细胞周期,参与细胞增殖和分化方面的证据也越来越多地被人们发现.为了探讨HSP27在表皮中的表达及其与皮肤肿瘤中细胞增殖和细胞分化的关系,我们采用免疫组化法检测HSP27、增殖细胞核抗原(PCNA)在皮肤基底细胞癌、鳞状细胞癌中的表达.     

皮肤基底细胞癌和鳞状细胞癌的研究现状

基底细胞癌和鳞状细胞癌是最常见的非黑素瘤皮肤癌。近年来，其发病率持续上升，引起临床较多的关注，研究发现紫外线照射、人类乳头瘤病毒感染、癌基因突变等因素与它们的发病密切相关。诱发该类疾病的机制也是多种多样的。除了传统治疗方法，Mohs外科切除术、光动力学疗法、新药的应用等也为该病的治疗提供了新方法。另外，脂取积极的预防措施可有效地防止基底细胞癌和鳞状细胞癌的发生。     

超氧化物歧化酶在基底细胞癌和鳞状细胞癌发病中的意义

我们采用逆转录聚合酶链反应(RT-PCR)和免疫印迹技术研究了正常暴光、非暴光部位皮肤和皮肤癌、癌周正常组织中锰SOD(MnSOD)和铜锌SOD(CuZnSOD)的mRNA及蛋白表达,初步探讨其表达在皮肤癌发生中的意义。     

Fas/FasL在基底细胞癌和鳞状细胞癌中的表达

目的:检测Fas/FasL在基底细胞癌(BCC)和鳞状细胞癌(SCC)中的表达.方法:采用SABC技术分别检测Fas/FasL在BCC、SCC及正常人对照皮肤中的表达.结果:Fas/FasL在BCC组不表达或弱表达,较正常人组无显著差异(P＞0.05);SCC组Fas和FasL的表达均高于对照皮肤(P＜0.05和＜0.01).Fasl染色主要集中于肿瘤细胞,弥漫染色,在肿瘤团块边缘表达更强;Fas在角珠处表达较强.结论:FasL在基底细胞癌不表达或弱表达,表明BCC侵袭扩散能力低,而在鳞状细胞癌中高表达可能与肿瘤的侵袭扩散能力高有关.     

皮肤基底鳞状细胞癌1例

1临床资料，患者女，62岁。前额肿物缓慢生长1年半，破溃30天，患者1年半前无明显诱因前额中央出现一红褐色丘疹，黄豆大小，进行性增大如拇指大小，表面略粗糙。     

皮肤鳞状细胞癌,基底细胞癌,恶性黑素瘤449例统计分析

皮肤鳞状细胞癌、基底细胞癌、恶性黑素瘤４４９例统计分析孙桂珍，张宗琴，朱晓琳，蓝毓滨，李春梅，宁晓明皮肤鳞状细胞癌（ＳＣＣ），基底细胞癌（ＢＣＣ），恶性黑素瘤（ＭＭ）是皮肤科常见的恶性肿瘤，我们统计了１９７８年１月～１９９２年１２月（１９９０年末统计...     

Photodynamic therapy for the treatment of a giant superficial basal cell carcinoma

A 74-year-old man was referred to our department for the treatment of a 15 × 15 cm superficial basal cell carcinoma (BCC) on his lumbar region. As surgical excision was considered too destructive, photodynamic therapy (PDT) was proposed. Methyl 5-aminolevulinate (MAL) cream was applied under occlusion for 3 h before illumination with a light-emitting diode lamp with an emission peak of 632 nm, a fluence rate of 83.3 mW/cm, and a light dose of 37 J/cm. A second MAL-PDT session was repeated 1 week later. The neoplastic area healed in 30 days. No recurrence has occurred after a 40-month follow-up period, but clinical observation continues. Although surgery still remains the treatment of choice for giant BCC, for which the local invasiveness and metastatic potential are well known, we offered our patient the option of PDT because we believed that classical surgery could hardly provide the same satisfactory outcome. As far as we know, this is the first case of giant BCC treated with PDT.     

Surgical margins of excision for basal cell carcinoma and squamous cell carcinoma

In excising basal and squamous cell carcinomata, the surgical margin that is wide enough to completely remove the tumor an acceptable percentage of the time and narrow enough to minimize removal of excessive normal tissue must be selected. This task can be reliably accomplished with comprehensive knowledge of factors that affect subclinical tumor extension such as tumor appearance, diameter, histology, location, treatment status, and, in the case of squamous cell carcinoma, vertical invasion depth and involvement of subcutaneous fat. Information regarding these factors along with specific recommendations about excisional margins for basal cell and squamous cell carcinomata is presented.     

钬激光联合光动力治疗头面部难治性基底细胞癌和鳞状细胞癌疗效评价

目的:评价钬激光联合光动力治疗19例基底细胞癌(BCC)及7例头面部鳞状细胞癌(SCC)的临床疗效。方法:首先采用钬激光对病变组织进行消融,再使用光动力进行联合治疗,随访12~18个月。结果:10例皮损完全消退(BCC8例、SCC2例);9例(BCC6例、SCC3例)皮损缩小≥50%;复发6例(BCC4例、SCC2例),总有效率73.08%。结论:钬激光联合光动力治疗头面部BCC和SCC有效。     

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

BACKGROUND: Imiquimod 5% cream has been investigated for non-surgical treatment of superficial and nodular basal cell carcinoma (BCC) tumours. OBJECTIVES: Two studies were conducted to examine the effect of occlusion at low dosing frequencies on the safety and efficacy of topical imiquimod 5% cream for the treatment of superficial and nodular BCC. PATIENTS AND METHODS: Both open-label studies were conducted in Europe. Patients diagnosed with BCC were enrolled into either the superficial (93 patients) or nodular (90 patients) study, depending on the histological confirmation of the patient's tumour subtype. Patients were randomized to one of four groups to apply imiquimod 5% cream 2 or 3 days per week either with or without occlusion. Six weeks following a 6-week treatment period, the entire target tumour area was excised and histologically examined for evidence of residual tumour. RESULTS: In both studies, the highest histologically complete response rate was seen in the 3 days per week with occlusion groups, with complete response rates of 87% and 65% for the superficial and nodular studies, respectively. Occlusion did not have a statistically significant effect on response rate at either dosing frequency. Response rates for superficial and nodular BCC tumours treated 3 days per week without occlusion were 76% and 50%, respectively. CONCLUSIONS: In the superficial study, the complete response rate of 87% in the 3 days per week with occlusion group was similar to that of daily and 5 days per week dosing without occlusion in a previous 12-week study and one study of daily dosing without occlusion for 6 weeks. All treatment groups had acceptable safety profiles in both studies. Occlusion did not have a statistically significant effect on efficacy for either superficial or nodular BCC tumours.     

SGK1在日光性角化病、基底细胞癌及鳞状细胞癌中的表达

目的：检测SGK1在日光性角化病（AK）、基底细胞癌（BCC）及鳞状细胞癌（SCC）中的表达。方法：采用免疫组化SABC法检测SGK1在25例正常皮肤(NS)、25例AK、28例BCC、28例皮肤鳞状细胞癌标本中的表达。结果：NS、AK、BCC和SCC标本中,SGK1阳性细胞率分别为（40.03±14.42）%,（36.63±14.28）%,（52.82±18.73）%和（52.58±20.13）%。BCC组和SCC组分别与NS组比较,差异均有统计学意义（Ps<0.05）。各组SGK1染色阳性细胞率>50%的标本分别为6例（24%）,3例（12%）,16例（57.14%）和14例（50%）,BCC组和SCC组分别与NS组比较,差异均有统计学意义（Ps<0.05）。结论：SGK1的高表达可能与基底细胞癌及鳞状细胞癌的发病有关。     

组织蛋白酶D在皮肤鳞状细胞癌、基底细胞癌和脂溢性角化病的组织表达及其意义

目的：观察组织蛋白酶D（cathepsinD，CD）在皮肤鳞状细胞癌（SCC）、基底细胞癌（BCC）、脂溢性角化病（SK）的组织表达，分析其表达差异及其意义。方法：用免疫组化SP染色法检测CD在15例SCC、15例BCC、14例SK及10例正常对照皮肤组织中的表达。结果：CD在正常皮肤组织表达为阴性．在SK、BCC、SCC瘤组织中表达依次升高，在SCC、SK之间表达有显著性差异（P〈0．05）；CD在SK、BCC、SCC间质细胞表达阳性率分别为85．7％、66，7％、33．3％。结论：CD的表达水平可能与SCC侵袭和转移有关。     

Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities

Basal cell carcinoma (BCC) is the most common malignancy in Caucasians, and its incidence is increasing. Most BCCs are treated surgically, nevertheless surgery is not an effective treatment for locally advanced or metastatic BCC. Alterations in hedgehog signaling pathway, a key regulator of cell growth and differentiation during development, are implicated in the pathogenesis of basal‐cell carcinoma. Vismodegib is a small‐molecule inhibitor of smoothened (SMO), a key component of the hedgehog (Hh) signaling pathway, administered in BCC patients, especially when surgery and radiotherapy treatments have failed. We report a series of eight elderly patients treated with vismodegib for advanced BCC and affected by concomitant multiple comorbidities. The efficacy and tolerability of vismodegib in patients with single and/or multiple comorbidities has been poorly studied. In our observation an overall high safety and tolerability has been observed over the course of treatment, with side effects of grade I and II and no changes in vital parameters, electrocardiography and echocardiogram. Vismodegib has been shown to be a safe and well tolerated treatment option for elderly patients affected by multiple comorbidities and advanced BCC.